Atopic dermatitis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 61: Line 61:
|-
|-
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic contact dermatitis
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 90: Line 90:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Irritant contact dermatitis
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 119: Line 119:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Seborrheic dermatitis
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Seborrheic dermatitis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 148: Line 148:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Psoriasis
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 177: Line 177:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Lichen simplex chronicus
! align="center" style="background:#DCDCDC;" |[[Lichen simplex chronicus]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 206: Line 206:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Ichthyosis vulgaris
! align="center" style="background:#DCDCDC;" |[[Ichthyosis vulgaris]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 235: Line 235:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Nummular Dermatitis
! align="center" style="background:#DCDCDC;" |[[Nummular dermatitis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 264: Line 264:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Netherton syndrome
! align="center" style="background:#DCDCDC;" |[[Netherton's syndrome]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 293: Line 293:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Dubowitz syndrome
! align="center" style="background:#DCDCDC;" |[[Dubowitz syndrome]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 352: Line 352:
|-
|-
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Dermatophytes
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 381: Line 381:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Candida
! align="center" style="background:#DCDCDC;" |[[Candidiasis|Candida]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 410: Line 410:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Herpes simplex
! align="center" style="background:#DCDCDC;" |[[Herpes simplex]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 439: Line 439:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Staphylococcus aureus
! align="center" style="background:#DCDCDC;" |[[Staphylococcus aureus]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 468: Line 468:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Molluscum Contagiosum
! align="center" style="background:#DCDCDC;" |[[Molluscum contagiosum]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 497: Line 497:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Scabies
! align="center" style="background:#DCDCDC;" |[[Scabies]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 526: Line 526:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |HIV
! align="center" style="background:#DCDCDC;" |[[Human Immunodeficiency Virus (HIV)|HIV]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 587: Line 587:
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunologic disorders
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunologic disorders
! align="center" style="background:#DCDCDC;" |Dermatitis herpetiformis
! align="center" style="background:#DCDCDC;" |[[Dermatitis herpetiformis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 616: Line 616:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Pemphigus foliaceus
! align="center" style="background:#DCDCDC;" |[[Pemphigus foliaceus]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 645: Line 645:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Graft-versus-host disease
! align="center" style="background:#DCDCDC;" |[[Graft-versus-host disease]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 674: Line 674:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Dermatomyositis
! align="center" style="background:#DCDCDC;" |[[Polymyositis and dermatomyositis|Dermatomyositis]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 704: Line 704:
|-
|-
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immune deficiency
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immune deficiency
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Wiskott-Aldrich syndrome
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Wiskott-Aldrich syndrome]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 733: Line 733:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Hyper-IgE syndrome
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyper-IgE syndrome]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 762: Line 762:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |DiGeorge syndrome
! align="center" style="background:#DCDCDC;" |[[22q11.2 deletion syndrome|DiGeorge syndrome]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 791: Line 791:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Severe combined immunodeficiency (SCID)
! align="center" style="background:#DCDCDC;" |[[Severe combined immunodeficiency]] ([[Severe combined immunodeficiency|SCID]])
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 820: Line 820:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Ataxia telangiectasia
! align="center" style="background:#DCDCDC;" |[[Ataxia telangiectasia]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 881: Line 881:
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic Diseases
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic Diseases
! align="center" style="background:#DCDCDC;" |Phenylketonuria
! align="center" style="background:#DCDCDC;" |[[Phenylketonuria]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 910: Line 910:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Tyrosinemia
! align="center" style="background:#DCDCDC;" |[[Tyrosinemia]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 939: Line 939:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Histidinemia
! align="center" style="background:#DCDCDC;" |[[Histidinemia]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 968: Line 968:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Multiple carboxylase deficiency
! align="center" style="background:#DCDCDC;" |[[Multiple carboxylase deficiency]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 998: Line 998:
|-
|-
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional deficiencies
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional deficiencies
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Zinc deficiency
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Zinc deficiency]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 1,027: Line 1,027:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Niacin (B3) deficiency
! align="center" style="background:#DCDCDC;" |[[Pellagra|Niacin (B3) deficiency]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 1,056: Line 1,056:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Pyridoxine (B6) deficiency
! align="center" style="background:#DCDCDC;" |[[Pyridoxine deficiency|Pyridoxine (B6) deficiency]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 1,085: Line 1,085:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Biotin (B7) deficiency
! align="center" style="background:#DCDCDC;" |[[Biotin deficiency|Biotin (B7) deficiency]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 1,115: Line 1,115:
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycosis fungoides
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cutaneous T cell lymphoma|Mycosis fungoides]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 1,144: Line 1,144:
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Histiocytosis X
! align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis|Histiocytosis X]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
Line 1,174: Line 1,174:
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications
! align="center" style="background:#DCDCDC;" |Infliximab
! align="center" style="background:#DCDCDC;" |[[Infliximab]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  

Revision as of 17:04, 11 October 2018

Atopic dermatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atopic dermatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis differential diagnosis

CDC on Atopic dermatitis differential diagnosis

Atopic dermatitis differential diagnosis in the news

Blogs onAtopic dermatitis differential diagnosis

Directions to Hospitals Treating Atopic dermatitis

Risk calculators and risk factors forAtopic dermatitis differential diagnosis

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.


Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis differential diagnosis

CDC on Atopic dermatitis differential diagnosis

Atopic dermatitis differential diagnosis in the news

Blogs on Atopic dermatitis differential diagnosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Atopic dermatitis differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

Differentiating [Disease name] from other Diseases

    • Seborrhoeic dermatitis
      • onset during the 1st days or weeks of life, absence of pruritus, and presence of greasy scaling on a yellow-red base
      • Involvement of the top of the scalp (cradle cap), axilla, and diaper area makes it more likely the patient has seborrheic dermatitis, vs excoriated dermatitis involving the extensor surfaces, face, and trunk favour AE.
    • Sarcoptes scabiei
      • highly pruritic, erythematous papular lesions. In most cases, the typical burrows can be found on the flexor wrists, finger webs and genitalia. Similar symptoms in other family members
Category Diseases Etiology Inherited Acquired Clinical manifestations Para-clinical findings Gold standard Additional findings
Demography History Symptoms Physical examination
Lab Findings Imaging Histopathology
Appearance Itching Bleeding Fever BP Tenderness Nail pitting Other CBC ESR/CRP Electrolytes BUN/Cr LFT
Single/

Multiple

Rash Involved areas Pustule WBC Hb Plt
Skin disorders Allergic contact dermatitis
Irritant contact dermatitis
Seborrheic dermatitis
Psoriasis
Lichen simplex chronicus
Ichthyosis vulgaris
Nummular dermatitis
Netherton's syndrome
Dubowitz syndrome
Erythrokeratodermia variabilis
Infection Dermatophytes
Candida
Herpes simplex
Staphylococcus aureus
Molluscum contagiosum
Scabies
HIV
Category Diseases Etiology Inherited Acquired Demography History Single/

Multiple

Rash Involved areas Pustule Itching Bleeding Fever BP Tenderness Nail pitting Other WBC Hb Plt ESR/CRP Electrolytes BUN/Cr LFT Imaging Histopathology Gold standard Additional findings
Immunologic disorders Dermatitis herpetiformis
Pemphigus foliaceus
Graft-versus-host disease
Dermatomyositis
Immune deficiency Wiskott-Aldrich syndrome
Hyper-IgE syndrome
DiGeorge syndrome
Severe combined immunodeficiency (SCID)
Ataxia telangiectasia
Category Diseases Etiology Inherited Acquired Demography History Single/

Multiple

Rash Involved areas Pustule Itching Bleeding Fever BP Tenderness Nail pitting Other WBC Hb Plt ESR/CRP Electrolytes BUN/Cr LFT Imaging Histopathology Gold standard Additional findings
Metabolic Diseases Phenylketonuria
Tyrosinemia
Histidinemia
Multiple carboxylase deficiency
Nutritional deficiencies Zinc deficiency
Niacin (B3) deficiency
Pyridoxine (B6) deficiency
Biotin (B7) deficiency
Malignancy Mycosis fungoides
Histiocytosis X
Medications Infliximab
Category Diseases Etiology Inherited Acquired Demography History Single/

Multiple

Rash Involved areas Pustule Itching Bleeding Fever BP Tenderness Nail pitting Other WBC Hb Plt ESR/CRP Electrolytes BUN/Cr LFT Imaging Histopathology Gold standard Additional findings

References


Template:WikiDoc Sources